Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
AssigneeScholar Rock, Inc.
InventorsAdriana Donovan, Michelle Straub, Stefan Wawersik
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
Claims19
A method for inhibiting myostatin activation in a human subject in need thereof, the method comprising a step of administering to the subject a composition comprising an antibody that blocks release of mature myostatin, in an amount effective to cause two or more of the following in the subject:
- (a) an increase in mass and/or function of a muscle tissue in the subject;
- (b) a decrease in ratio of adipose-to-muscle tissue in the subject;
- (c) a decrease in intramuscular fat infiltration in the subject;
- and
- (d) prevention of muscle loss or atrophy in the subject;
- wherein the antibody comprises a heavy chain sequence of SEQ ID NO:
- 50 and a light chain sequence of SEQ ID NO:
- 51.
A method for inhibiting myostatin activation in a human subject having spinal muscular atrophy (SMA), the method comprising a step of administering to the subject a composition comprising an antibody that blocks release of mature myostatin, in an amount effective to
- prevent muscle loss or atrophy in the subject;
- wherein the antibody comprises a heavy chain sequence of SEQ ID NO:
- 50 and a light chain sequence of SEQ ID NO:
- 51.
A method for inhibiting myostatin activation in a human subject having, or at risk of developing, a metabolic disorder, the method comprising a step of administering to the subject a composition comprising an antibody that blocks release of mature myostatin, in an amount effective to cause two or more of the following in the subject:
- (a) an increase in mass and/or function of a muscle tissue in the subject;
- (b) a decrease in ratio of adipose-to-muscle tissue in the subject;
- (c) a decrease in intramuscular fat infiltration in the subject;
- and
- (d) prevention of muscle loss or atrophy in the subject;
- wherein the antibody comprises a heavy chain sequence of SEQ ID NO:
- 50 and a light chain sequence of SEQ ID NO:
- 51.
Dependencies are inferred from the claim text.